These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 21144842

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Platinum agent-induced nephrotoxicity via organic cation transport system].
    Yonezawa A.
    Yakugaku Zasshi; 2012; 132(11):1281-5. PubMed ID: 23123720
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
    Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K.
    J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
    [Abstract] [Full Text] [Related]

  • 4. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.
    Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K.
    Biochem Pharmacol; 2007 Aug 01; 74(3):477-87. PubMed ID: 17582384
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug transporters of platinum-based anticancer agents and their clinical significance.
    Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA.
    Drug Resist Updat; 2011 Feb 01; 14(1):22-34. PubMed ID: 21251871
    [Abstract] [Full Text] [Related]

  • 12. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
    Cornelison TL, Reed E.
    Gynecol Oncol; 1993 Aug 01; 50(2):147-58. PubMed ID: 8375728
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
    Haschke M, Vitins T, Lüde S, Todesco L, Novakova K, Herrmann R, Krähenbühl S.
    Nephrol Dial Transplant; 2010 Feb 01; 25(2):426-33. PubMed ID: 19736245
    [Abstract] [Full Text] [Related]

  • 15. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    Ali BH, Al Moundhri MS.
    Food Chem Toxicol; 2006 Aug 01; 44(8):1173-83. PubMed ID: 16530908
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Saving ears and kidneys from cisplatin.
    Wensing KU, Ciarimboli G.
    Anticancer Res; 2013 Oct 01; 33(10):4183-8. PubMed ID: 24122981
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ, Friedlos F, Lydall DA, Roberts JJ.
    Cancer Res; 1986 Apr 01; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [Abstract] [Full Text] [Related]

  • 20. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.
    Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K.
    Drug Metab Dispos; 2008 Nov 01; 36(11):2299-306. PubMed ID: 18710896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.